PNC Financial Services Group Inc. Grows Stock Holdings in argenx SE (NASDAQ:ARGX)

PNC Financial Services Group Inc. lifted its stake in shares of argenx SE (NASDAQ:ARGX) by 13.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,538 shares of the company’s stock after purchasing an additional 181 shares during the period. PNC Financial Services Group Inc.’s holdings in argenx were worth $946,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. West Family Investments Inc. acquired a new position in argenx during the fourth quarter worth $251,000. Callan Family Office LLC purchased a new position in shares of argenx during the 4th quarter worth $396,000. Raymond James Financial Inc. acquired a new position in shares of argenx during the 4th quarter valued at about $43,543,000. Assetmark Inc. grew its holdings in shares of argenx by 11.3% in the fourth quarter. Assetmark Inc. now owns 8,648 shares of the company’s stock valued at $5,319,000 after purchasing an additional 879 shares during the period. Finally, J.Safra Asset Management Corp increased its position in argenx by 123.8% during the fourth quarter. J.Safra Asset Management Corp now owns 273 shares of the company’s stock worth $169,000 after purchasing an additional 151 shares during the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on ARGX shares. Oppenheimer boosted their target price on shares of argenx from $675.00 to $704.00 and gave the company an “outperform” rating in a report on Friday, February 28th. JMP Securities upped their price objective on argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a report on Tuesday, January 14th. Truist Financial reissued a “buy” rating and set a $700.00 target price (up previously from $660.00) on shares of argenx in a research note on Tuesday, January 14th. HC Wainwright upped their price target on argenx from $717.00 to $720.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Finally, Evercore ISI increased their price target on argenx from $675.00 to $706.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. Three investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, argenx currently has an average rating of “Moderate Buy” and an average target price of $687.00.

argenx Trading Up 1.5 %

Shares of NASDAQ ARGX opened at $614.19 on Tuesday. The stock has a market cap of $37.32 billion, a P/E ratio of -697.94 and a beta of 0.59. The business’s fifty day simple moving average is $637.58 and its 200-day simple moving average is $597.56. argenx SE has a 12-month low of $349.86 and a 12-month high of $678.21.

argenx (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. On average, equities analysts forecast that argenx SE will post 3.13 EPS for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.